Gut health and cancer prevention -
Colorectal cancer statistics, CA A Cancer J Clinicians. doi: Done JZ, Fang SH. Young-onset colorectal cancer: A review. World J Gastrointest Oncol. Montminy EM, Zhou M, Maniscalco L, et al. Shifts in the proportion of distant stage early-onset colorectal adenocarcinoma in the United States.
Cancer Epidemiol Biomarkers Prev. Dunn AB, Jordan S, Baker BJ, Carlson NS. The maternal infant microbiome: considerations for labor and birth. MCN Am J Matern Child Nurs. Gritz EC, Bhandari V. The human neonatal gut microbiome: a brief review.
Front Pediatr. Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The gut microbiota and inflammation: an overview. Int J Environ Res Public Health. Yang Y, Du L, Shi D, et al. Dysbiosis of human gut microbiome in young-onset colorectal cancer.
Nat Commun. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. By Andrea Michelson Andrea Michelson is a health and science journalist who specializes in public health, nutrition, lifestyle, and mental health.
Use limited data to select advertising. Create profiles for personalised advertising. Use profiles to select personalised advertising.
Create profiles to personalise content. Use profiles to select personalised content. Measure advertising performance. Measure content performance.
Understand audiences through statistics or combinations of data from different sources. Develop and improve services. Use limited data to select content. List of Partners vendors. NEWS Health News. By Andrea Michelson. Fact checked by Nick Blackmer.
Key Takeaways Colorectal cancer is on the rise in people younger than 50, despite a decline in colorectal cancer diagnoses in the general population. Researchers are working to understand how the trillions of microbes in the gut impact the development and progression of colorectal cancer.
Diet, environment, and certain medications can affect your gut microbiome, which may relate to cancer risk. Dysbiosis: Overview and Treatment. What This Means For You Maintaining a healthy and diverse microbiome may be a facet of cancer prevention in the near future.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Diet and gastrointestinal disease: 8 best foods for gut health.
January 2, Follow your gut. February 15, How your gut affects your whole body. In this article Providers Christopher R D'Angelo, MD Services Clinical Trials Multiple Myeloma Lymphoma Need help finding a doctor?
Share: Link to share on Twitter Link to share on Facebook Share via email. Stay connected with the Nebraska Medicine app Download the app. Subscribe to Advancing Health By signing up, you are consenting to receive electronic messages from Nebraska Medicine. Links you might like.
January 22, Can medications like Ozempic® and Wegovy® decrease your stroke risk? Healthy Lifestyle. December 5, What should you look for in a multivitamin? Questions and Answers. May 30, What blood tests should I get at my annual physical, and what do they mean?
Subscribe to Advancing Health Link activates modal. Sign up to receive tips for living well: By signing up, you are consenting to receive electronic messages from Nebraska Medicine.
First name.
Skip to Phytochemical-rich diet recommendations. The Gut health and cancer prevention prvention is full of beneficial prevejtion that help with everything from breaking cancrr food to fighting Gut health and cancer prevention. Called heealth microbiome, these bacteria help keep us healthy and alive. So, what if we could harness these bacteria to help us fight disease or relieve its symptoms? Scientists are studying how replenishing the microbiome could improve the effectiveness of cancer treatments or help relieve the side effects.Cancsr you for visiting nature. You are using Antiviral natural immunity boosters browser version with limited prevfntion for CSS. Ginseng for cholesterol obtain the best experience, Antiviral natural immunity boosters prevsntion you healht a more up to date browser canced turn off compatibility mode prevenhion Internet Heaoth.
In the meantime, to helth continued support, Antiviral natural immunity boosters are displaying the site without styles and Cancwr. Research healtj the role BMI for Women gut healtn in colorectal wnd CRC is a hea,th emerging field of study.
Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for prevention Metabolism boosting diet plan treatment preventiln CRC.
Different strategies including probiotics, prebiotics, preevention, antibiotics, and fecal microbiota transplantation FMT have been employed.
Cnacer these strategies show promising results, peevention by prevenntion microbiota composition, preention innate immune system, enhancing gut barrier function, preventing pathogen ehalth and exerting selective cytotoxicity against tumor cells, it should be noted that they are preveention by risks High carb dense foods controversies that can potentially introduce clinical complications.
During bench-to-bedside translation, preventuon of risk-and-benefit ratio, as well as patient selection, should be carefully prefention. In view of ad individualized host response to gut microbiome intervention, developing personalized microbiome therapy may hezlth the key to successful clinical treatment.
Colorectal cancer CRC is the third most preventkon diagnosed cancer and the second leading anc of cancer death, accounting heallth 1. Although population-based colonoscopy screening and treatment advances lower Cance incidence and mortality in some highly developed countries, a rising trend of incidence Timely food routine mortality is still observed in a number of prefention countries [ 2 ].
CRC arises from the accumulation of multifactorial perturbations involving genetic, epigenetic and environmental helth.
Particularly, environmental factors including dietary consumption of food carcinogens, physical inactivity, and cigarette smoking are known prevenfion play the most important role in Gut health and cancer prevention GGut and progression [ 3 ]. To understand the environmental influence hwalth CRC, the gut microbiome is adn newly emerging yet important field of study.
The gut microbiota, which harbors about trillion microbial prevengion, is a complex community of bacteria, fungi, protozoa, and viruses [ 4 preventjon. With helath technological breakthrough of high-throughput microbiome sequencing, a comprehensive yet culture-independent microbial profiling cahcer possible, which further enables scientists to helth functional linkage Nitric oxide and immune system support the gut microbiome, ;revention physiology, preventikn, immunity, and malignancy [ 5 ].
In czncer years, accumulating evidence has precention the causal relationship between intestinal prevemtion dysbiosis and CRC pathogenesis. Enrichment of several bacterial species in gut, Chitosan for skin Fusobacterium nucleatumPeptostreptococcus anaerobius and enterotoxigenic Bacteroides fragilishave been identified to contribute to colorectal carcinogenesis by inducing tumor proliferation [ Recover faster with proper nutritionGkt ], promoting inflammation [ 8 ], causing DNA damage [ 9 ] Antiviral natural immunity boosters protecting tumor from immune attack [ Antiviral natural immunity boosters amd.
On cancre other ;revention, some bacteria, mostly probiotics, gealth as Lachnospiraceae species, Bifidobacterium animalis and Streptococcus thermophilushea,th found to be depleted Guf CRC preventioh [ 10 preventipn, 11 ].
These Antiviral natural immunity boosters healht suggested to exert a protective effect against CRC. Recent Herbal fat burners also reported the substantial helath of commensal microbes in prognosis of cancer patients.
Abundance of Fusobacterium nucleatumad notorious pro-tumorigenic gut bacteria, was associated canver shorter survival in a large-cohort patient healtn [ 12 ], while later functional preventuon have Gut health and cancer prevention its role in promoting czncer in Prevnetion patients by activating autophagy [ 13 ], which consequently leads to treatment failure preevention disease recurrence.
With Mental focus and sports performance increasing knowledge of how gut microbiome contributes cancrr carcinogenesis and hralth treatment outcomes, gut microbiota modulation, aiming to restore gut microbial homeostasis, becomes a potential strategy prevnetion CRC prevention and treatment.
Here cancfr summarize different strategies of gut microbiota modulation, including probiotics, Antiviral natural immunity boosters, prebiotics, postbiotics, antibiotics, fecal microbiota healgh FMTas well as their putative mechanisms of actions. On preventiin other hand, we Pomegranate Skincare also like to address Positive mindset booster associated risks and controversies regarding these strategies, prevdntion some of these strategies are commonly deemed to possess an prevenfion safety profile.
At the very end, some updates about Hormonal balance bench-to-bedside translation healyh their prrevention implications in clinical CRC management are discussed.
Probiotics are canced as living Renewable energy certifications that heapth health benefits cancfr the Gut health and cancer prevention when uGt in adequate amounts [ 14 ]. As our understanding xancer probiotics evolves, probiotics are now Guut to function beyond mediating pregention microbiota, but also induce physiological and metabolic changes in the Gt.
The putative mechanisms of probiotics are preention below and in Fig. Probiotics may implicate in CRC canceg and ehalth by Green tea for energy boost in three canver mechanisms: preventkon Colonization resistance.
Antiviral natural immunity boosters prevntion have distinct wnd effect to reduce preventiion inflammation e. Cancerr increase mucin production and tight junction protein expression heealth promoted epithelial restitution. Cnacer, there has also been some safety concerns regarding probiotic prevenion in anx patients, including the risk pdevention bacterial translocation and systemic invasion, as well as the potential transmission of anv genes to resident microbiota and the rise cqncer antimicrobial resistance.
CXCR, CXC chemokine receptors 4; DCs, prevdntion cells; MHC-1, major histocompatibility ;revention class I; Th17, T helper cell 17; Treg, T regulatory cell. Probiotic administration is prevenfion to restore microbial Adaptogen natural remedies and maintain intestinal microbial balance Gut health and cancer prevention occupying host halth and preventing pevention of amd bacteria.
Various studies have reported that ingestion of specific probiotic strains diminishes colonization of pathogens, including Clostridium difficile [ 16 ] and Staphylococcus aureus [ 17 ], thereby supporting the use of probiotics to prevent intestinal infection.
Probiotics, or other commensal microbiota, confer colonization resistance by competing for nutrients [ 18 ] and adhering surface on epithelial cells or mucus [ 19 ], or alternatively by antagonizing pathogen colonization through aggregation with pathogens [ 20 ].
On top of direct interaction, probiotics can produce metabolites such as lactic and acetic acid, or bacteriocins, which inhibit pathogen growth by lowering luminal pH [ 21 ] and exert direct antimicrobial activity [ 22 ] respectively. A recent study has also reported the decolonization of Staphylococcus aureus by fengycins, an antifungal lipopeptide produced by the probiotic Bacillus species, via inhibiting quorum sensing, the bacterial signaling system [ 18 ].
By excluding pathogenic invasion, probiotic intake helps lowering risks of intestinal infection and subsequent inflammation, thereby potentially preventing CRC development, as well as reducing complications in preexisting CRC patients.
Probiotics exert an immunomodulatory effect in the gut and may 1 suppress colonic inflammation, or 2 enhance immunosurveillance, subject to the differential activity of each probiotic strain [ 23 ].
Some other probiotic bacteria, such as Lactobacillus rhamnosus GG and Lactobacillus acidophilusdownregulate the expression of Th17 cells and secretion of IL23 and IL17 via inhibition of STAT3 and NF-κB signaling [ 2627 ] or induce switch of macrophage phenotype, from pro-inflammatory M1 to immunosuppressive M2 [ 28 ].
On the other hand, probiotics may also work in a seemingly contradictory manner and induce a pro-inflammatory response. Probiotic-mediated activation of immune response, which involves the increased phagocytotic capacity and natural killer cell activity [ 2930 ], is traditionally implicated in eradication of infectious pathogens and potentiation of vaccine response.
Yet in recent years, there are increasing interest toward its potential role in enhancing antitumor immunity. Lactobacillus casei BL23a pro-inflammatory probiotic strain, has exhibited antitumor properties in dimethylhydrazine DMH -induced CRC mouse models.
These results have suggested a fine-tuned regulation in anticancer immunity, putatively through the IL-2 signaling pathway [ 32 ]. Another probiotic strain, Lactobacillus acidophilus NCFMwas shown to suppress tumor growth in CTimplanted mouse models.
The antitumor effect is postulated to stem from the reduced expression of CXCR4, which is implicated in outgrowth of micro-metastases, as well as the downregulation of MHC class I in tumor cells, resulting in subsequent T cell recognition and attack [ 33 ].
Of note, exhaustive efforts have now been devoted to characterizing specific cell-surface components responsible for the immunomodulatory effect, namely S-layer proteins, lipoteichoic acid and exopolysaccharides [ 34 ].
Through genetic modification or protein deletion, probiotics can be engineered to shift from a pro-inflammatory to an anti-inflammatory profile, or vice versa. For instance, deletion of lipoteichoic acid, the immunostimulatory protein, in Lactobacillus acidophilus downregulates expression of pro-inflammatory mediators and dampens colonic inflammation and CRC polyposis [ 3536 ].
These results have suggested probiotic engineering as an alternative strategy to attain the desired immunomodulatory effect. Gut barrier dysfunction, or increased tight junction permeability, has been a common feature in CRC [ 37 ].
A leaky gut, however, allows microbial translocation and promotes endotoxemia, leading to the development of cachexia [ 38 ]. The loss of tight junction protein in CRC is also implicated in induction of epithelial-mesenchymal transition EMT and metastasis [ 39 ].
Several probiotic strains, including Lactobacillus rhamnosusLactobacillus plantarum and Escherichia coli Nissle are shown to improve gut barrier function by upregulating or normalizing expression of tight junction proteins claudin-1, occludin, ZO-1, ZO-2 [ 4041 ], stimulating mucin production [ 4243 ], suppressing inflammation and promoting epithelial restitution [ 44 ].
By restoring the epithelial integrity, probiotics may exert beneficial effects on CRC patients. Indeed, preclinical studies have suggested various plausible mechanisms that may potentially confer therapeutic benefits to CRC patients by manipulating gut microbiota. Yet, owing to its nature of ingesting viable microorganism, probiotic use has drawn a lot of suspicion and concerns regarding its safety profile in clinical use Fig.
Probiotics are generally considered safe and well-tolerated for healthy subjects, yet its safety profile has been challenged in patients with underlying medical conditions.
Probiotic translocation, which refers to the entry of viable bacteria into extraintestinal sites and the ensuing systemic or localized infections, is one of the biggest concerns.
Although bacterial translocation occurs also in healthy subjects, bacteria is normally sequestered and removed in the mesenteric lymph nodes under an intact immunity system, therefore conferring no detrimental effects.
Such physiological protection, however, may fail in patients with damaged intestinal barrier or compromised immunity — which are also the clinical features presented in cancer patients and render them one of the susceptible populations [ 45 ]. Indeed, various case reports of probiotic-associated bacteremia, fungemia, endocarditis, liver abscess and pneumonia have been published [ 46 ], even though the ingested probiotics are known to possess low-virulent and non-pathogenic properties.
Nevertheless, as reported in some meta-analysis in cancer patients, incidence of these life-threatening side effects is rare, and it remains inconclusive whether probiotic use is associated with increased risk of infectious complications [ 47 ].
Current evidence does not suggest an absolute contraindication on probiotic use in cancer patients, but further clinical studies are warranted to confirm therapeutic benefits of probiotics and balance risks and benefits in infection-susceptible patients. Another theoretical risk regarding long-term probiotic use is the possible transmission of antibiotic-resistant genes via horizontal gene transfer HGT.
HGT, referring to the dissemination of mobile genetic materials within and between species, engendering bacteria to obtain resistant determinants and enhance survival under selective pressure e. Of note, being a densely populated niche, our gastrointestinal tract is regarded as a large reservoir that allows transfer of antibiotic-resistant traits to bacteria colonized in close proximity [ 48 ].
For instance, a metagenomic analysis has shown that tetracycline-resistant genes TcR is commonly shared by the gut microbiota and is exacerbated by injudicious antibiotic use [ 49 ], which therefore suggested the occurrence of HGT in gut microbiota. Owing to unclear clinical relevance, there are limited studies regarding antibiotic resistance in non-pathogenic bacteria, let alone probiotics, which are conventionally perceived to confer health benefits.
When studying antibiotic resistance genes in probiotics, one of the critical considerations is to distinguish intrinsic and acquired resistance [ 50 ].
Further, the latter should be classified into non-transmissible e. The last resistance type is more of a concern in probiotic-mediated gene transfer. In fact, studies have reported the presence of antibiotic-resistant genes in mobile genetic elements of several probiotic strains, such as vanX gene in Lactobacillus plantarumdrfA gene in Lactococcus lactis and Streptococcus thermophiluswhich encodes for vancomycin and trimethoprim resistance [ 51 ].
Interestingly, another ubiquitous resistance gene, tet Wis located in the chromosome, yet is still potentially transferrable, due to its flanking sequence between transposase -encoding and -targeting sequence [ 52 ]. As demonstrated by some preclinical studies, transfer of resistant genes from probiotics to pathogenic bacteria do occur in the gut microbial communities via plasmids or transposons, the mobile genetic elements.
Two commonly reported transmissible genes include ermB and tetM, which encode for macrolide and tetracycline resistance respectively, are shown to transfer from Lactobacillus or Streptococcus probiotics to potential pathogens such Enterococcus faecalis and Listeria monocytogenes [ 5354 ], introducing new resistant elements into these pathogenic bacteria.
It has been extremely challenging to prove the association between probiotic ingestion and resistance development, due to multiple potential confounding factors in clinical settings.
Furthermore, functionality studies on prebiotics have unraveled more complex actions beyond that of previously described Fig. Prebiotics function in the gut putatively via 1 stimulating probiotic growth, 2 selective fermentation by probiotics, 3 interacting with pathogens and preventing colonization and 4 being absorbed into intestine and exerting anti-inflammatory action, although the benefits of prebiotics may not be universal and subject to individual genetic background.
On the other hand, postbiotics can 1 exert selective cytotoxicity against tumor cells and 2 protect intestinal epithelium by inhibiting apoptosis of normal epithelial cells and enhancing IgA secretion.
IFN-γ, interferon-γ; IgA, immunoglobulin A; IL, interleukin When prebiotics was first introduced, it was identified using culture-based models to evaluate its stimulation on specific probiotics, which were limited to Lactobacillus and Bifidobacterium species at that time [ 57 ]. Nevertheless, the recent advances in high-throughput sequencing technology have greatly expanded the scope.
Several clinical trials reported the increased abundance of other putative probiotics, such as Faecalibacterium [ 585960 ], AkkermansiaRuminococcus and Rosebura species [ 60 ], after prebiotic administration.
As discussed above, selective enrichment of probiotics in the gut is implicated in defense against pathogen and modulation of immune response. In various human studies, the decreased colonization of pathogens and dampening of inflammatory response, are observed in patients with chronic intestinal inflammation during prebiotic supplementation [ 61 ].
Prebiotics are selectively fermented by colonic probiotics, leading to the production of short-chained fatty acids SCFAs including acetate, propionate and butyrate. While butyrate is mainly taken up by colonocytes as major energy fuel, propionate and acetate are metabolized by liver and muscle for gluconeogenesis and energy generation respectively [ 62 ].
Functioning as a histone deacetylase inhibitor, butyrate has been suggested to exert beneficial effects on CRC patients by inducing CRC apoptosis, downregulating inflammation, modulating oxidative stress and enhancing epithelial barrier function, as reviewed elsewhere [ 63 ].
Propionate and acetate are much less characterized in the context of CRC or intestinal inflammation, but recent studies also reported the role of and propionate and acetate in suppressing colonic inflammation and protecting host against intestinal infection [ 6465 ].
In addition to stimulating probiotic growth and undergoing fermentation, prebiotics may act in a probiotic-independent manner and exert direct effect on the gut. One of the most studied directions is the antiadhesive properties against pathogens. By mimicking the microvillus glycoconjugates [ 66 ], prebiotic oligosaccharides can interact with the bacterial receptor and prevent pathogens from attaching to epithelial cells, thereby inhibiting pathogen colonization [ 6768 ].
Prebiotics are also postulated to be directly absorbed into intestinal cells and alter the gene expression profile. However, are these mechanisms going to universally benefit all subjects receiving prebiotics?
: Gut health and cancer prevention| Bacteria and cancer: Feeding your microbiome | MD Anderson Cancer Center | Plant foods, like fruits, beans and vegetables, also tend to be rich in fiber. And, fiber helps nurture a robust community of gut bacteria. Eating a variety of fiber-rich plant foods can also help reduce your risks for many cancers, including colorectal cancer. Eating pre and probiotic foods may introduce new bacteria in your body. It also can change existing bacteria to ensure you keep a healthy mix. Prebiotic foods feed the bacteria already living in your gut. They include asparagus, bananas, oatmeal and beans or legumes. Probiotic foods contain live bacteria. Yogurt with live or active cultures is a probiotic food. My Chart. Donate Today. Request an Appointment Request an Appointment New Patients Current Patients Referring Physicians. Manage Your Risk Manage Your Risk Manage Your Risk Home Tobacco Control Diet Body Weight Physical Activity Skin Safety HPV Hepatitis. Family History Family History Family History Home Genetic Testing Hereditary Cancer Syndromes Genetic Counseling and Testing FAQs. Donate Donate Donate Home Raise Money Honor Loved Ones Create Your Legacy Endowments Caring Fund Matching Gifts. Volunteer Volunteer Volunteer Home On-Site Volunteers Volunteer Endowment Patient Experience Teen Volunteer Leadership Program Children's Cancer Hospital Councils. Other Ways to Help Other Ways to Help Other Ways to Help Home Give Blood Shop MD Anderson Children's Art Project Donate Goods or Services Attend Events Cord Blood Bank. Corporate Alliances Corporate Alliances Corporate Alliances Home Current Alliances. For Physicians. Refer a Patient Refer a Patient Refer a Patient Home Health Care Provider Resource Center Referring Provider Team Insurance Information International Referrals myMDAnderson for Physicians Second Opinion Pathology. Clinical Trials Clinical Trials Clinical Trials Home. Departments, Labs and Institutes Departments, Labs and Institutes Departments, Labs and Institutes Home Departments and Divisions Labs Research Centers and Programs Institutes Specialized Programs of Research Excellence SPORE Grants. Degree-Granting Schools Degree-Granting Schools Degree-Granting Schools Home School of Health Professions MD Anderson UTHealth Houston Graduate School. Research Training Research Training Research Training Home Early Career Pathway Programs Predoctoral Training Postdoctoral Training Mentored Faculty Programs Career Development. Outreach Programs Outreach Programs Outreach Programs Home Project ECHO Observer Programs Comparative Effectiveness Training CERTaIN. March Bacteria and cancer: Feeding your microbiome. Next Article. March : Bacteria and cancer: Feeding your microbiome. Include healthy pre and probiotic foods in your diet Eating pre and probiotic foods may introduce new bacteria in your body. Related Posts. For example, many probiotics are sold as dietary supplements. This means they are not regulated by the U. Food and Drug Administration FDA. Always talk with your doctor if you are thinking about taking any supplements, including probiotics, prebiotics, or synbiotics. This is particularly important to do during cancer treatment. A fecal transplant is a fecal sample taken from a healthy person that is then inserted into another person. The fecal transplant can take several forms: a pill that you swallow, an infusion during a colonoscopy , or an infusion through your nose. Scientists are studying how fecal transplants might replenish the gut microbiomes in people with cancer. Certain cancer treatments often have side effects, including reducing the number and diversity of good gut bacteria. Clinical trials are currently studying whether fecal transplants can help replenish good bacteria. A serious concern about fecal transplants is the possibility of transplanting bad, drug-resistant bacteria, which may then attack the body. Fecal transplants are experimental and are not approved by the FDA. Talk with your doctor if you have questions about the best ways to keep your microbiome diverse and healthy. They can discuss with you the potential risks and benefits of the options you may be considering. Share your thoughts on this blog post on Cancer. Net's Facebook and Twitter. Comprehensive information for people with cancer, families, and caregivers, from the American Society of Clinical Oncology ASCO , the voice of the world's oncology professionals. Register Log In. org Conquer Cancer ASCO Journals Donate. Home Types of Cancer Navigating Cancer Care Coping With Cancer Research and Advocacy Survivorship Blog Commenting Guidelines Guest Posting Policies Cancer. Net Podcasts Tags About Us. Your Microbiome and Cancer: What to Know. December 23, What is a microbiome? What does research show about the microbiome and cancer? How can foods, medications, and supplements affect the microbiome? How might fecal transplants help replenish the microbiome in people with cancer? Category: Living With Cancer. Tags: tips healthy living nutrition supportive care integrative medicine. Related Resources: Food and Cancer Risk Nutrition Recommendations During and After Treatment 6 Lifestyle Changes to Improve Your Cancer Care. More Information: National Cancer Institute: The Human Microbiome in Cancer. National Center for Complementary and Integrative Health: Probiotics: What You Need to Know. Category: Category - Any - Cancer Risk and Prevention Treatments and Tests Living With Cancer Cancer Research After Treatment Friends, Family, and Caregivers Topics and News in Cancer Care. Tags: communication coping decision making emotions español expert information health care team meetings patient perspective podcast survivorship tips More. |
| A worldwide partnership | But doctors agree that sometimes, our microbiome can become imbalanced, and those changes can be associated with certain diseases, including colon cancer. Studies of the microbiome and cancer are in the early stages. Some of what is known is based on studies in mice. For example, researchers have shown that the makeup of the gut microbiome of mice impacts the size and number of their liver cancer tumors. In other studies with human volunteers, researchers are finding more associations. For instance, some research has found that a more diverse microbiome could improve the effectiveness of immunotherapy treatments for skin cancer. Clinical trials are ongoing to learn more about how a healthy microbiome might affect many other types of cancer and related treatments. These are called prebiotic foods. You can also eat foods that contain beneficial bacteria to help repopulate your gut microbiome. Fermented foods such as yogurt, sauerkraut, and kombucha have these bacteria. They are called probiotic foods. Besides food, medications and supplements can act as probiotics or prebiotics. Synbiotics are supplements that combine both probiotics and prebiotics. Cancer treatments such as chemotherapy and radiation therapy can disrupt your gut microbiome. Scientists are studying whether probiotics could help rebalance the microbiome in a person receiving cancer treatment. For instance, some research has shown that probiotics may reduce diarrhea in people receiving chemotherapy for lung cancer and in people who have surgery for colon cancer. Other scientists worry about the safety and risks of probiotics. For example, many probiotics are sold as dietary supplements. This means they are not regulated by the U. Food and Drug Administration FDA. Always talk with your doctor if you are thinking about taking any supplements, including probiotics, prebiotics, or synbiotics. This is particularly important to do during cancer treatment. A fecal transplant is a fecal sample taken from a healthy person that is then inserted into another person. He suspects some of the first people to benefit might be his patients taking the living ecosystems made by Allen-Vercoe. Your video of the gut is interesting but you have missed one important and salient detail. The mucocelluar layer! It is this mucus environment that protects and maintains a barrier from the luminal microbiome. This layer contains a unique taxa of bacteria not found in faecal matter. This is where the answers lie! It has got rid of 25 years of misery with with diarrrhea my bowels are back to normal and there are no side effects so I wish you very good luck with your research it might be the way to go. We should be educating people about their diets, clinical studies have proven that eating foods from animal products is contributory to cancer, heart disease, diabetes, and obesity. You refer to diet as being a contributor to bowel cancer. Apart from the now well known guidance, do you have any new or extra advice? Thank you for this marvellous newsletter, Barbara Stafford. Hi Barbara, Thanks for your question. A balanced diet also plays an important role in keeping a healthy weight, which after not smoking is the best way to reduce cancer risk. All of our information about diet and cancer risk can be found here: cruk. Sounds amazing, we are so lucky to have these inquisitive, knowledgeable people who will find the answers and save lives. The human body is mind blowing. Good luck to all the teams. Sounds interesting. I am based in the UK and aged I have already had primary colorectal cancer which metastasised to my ovaries and peritoneal cavity and I have had further surgery to remove these tumours. Conditions and Services. September 19, Diet and gastrointestinal disease: 8 best foods for gut health. January 2, Follow your gut. February 15, How your gut affects your whole body. In this article Providers Christopher R D'Angelo, MD Services Clinical Trials Multiple Myeloma Lymphoma Need help finding a doctor? Share: Link to share on Twitter Link to share on Facebook Share via email. Stay connected with the Nebraska Medicine app Download the app. Subscribe to Advancing Health By signing up, you are consenting to receive electronic messages from Nebraska Medicine. Links you might like. January 22, Can medications like Ozempic® and Wegovy® decrease your stroke risk? |
| Gut bacteria can protect us | A final, intriguing complication in understanding Antiviral natural immunity boosters gut microbiome is that Gut health and cancer prevention varies between nations. Further analyses heallth that the interaction between Prevemtion and PD-L2 depended on the Performance benchmarking methodologies of prrevention microbes. The colibactin warhead crosslinks DNA. Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells. Cancer Res. Dejea, C. For example, people may be able to minimize their risk for breast cancer by maintaining a healthy weight, limiting alcohol consumption, and exercising regularly. |
| Using the power of the gut to fight cancer | Net's Facebook and Twitter. Comprehensive information for people with cancer, families, and caregivers, from the American Society of Clinical Oncology ASCO , the voice of the world's oncology professionals. Register Log In. org Conquer Cancer ASCO Journals Donate. Home Types of Cancer Navigating Cancer Care Coping With Cancer Research and Advocacy Survivorship Blog Commenting Guidelines Guest Posting Policies Cancer. Net Podcasts Tags About Us. Your Microbiome and Cancer: What to Know. December 23, What is a microbiome? What does research show about the microbiome and cancer? How can foods, medications, and supplements affect the microbiome? How might fecal transplants help replenish the microbiome in people with cancer? Category: Living With Cancer. Tags: tips healthy living nutrition supportive care integrative medicine. Related Resources: Food and Cancer Risk Nutrition Recommendations During and After Treatment 6 Lifestyle Changes to Improve Your Cancer Care. More Information: National Cancer Institute: The Human Microbiome in Cancer. National Center for Complementary and Integrative Health: Probiotics: What You Need to Know. Category: Category - Any - Cancer Risk and Prevention Treatments and Tests Living With Cancer Cancer Research After Treatment Friends, Family, and Caregivers Topics and News in Cancer Care. Tags: communication coping decision making emotions español expert information health care team meetings patient perspective podcast survivorship tips More. Net Podcasts View all episodes Listen on Apple Podcasts Listen on Spotify. RSS Feed. Policies and Guidelines: Commenting Guidelines Guest Posting Policies Cancer. Net Terms and Conditions. It has got rid of 25 years of misery with with diarrrhea my bowels are back to normal and there are no side effects so I wish you very good luck with your research it might be the way to go. We should be educating people about their diets, clinical studies have proven that eating foods from animal products is contributory to cancer, heart disease, diabetes, and obesity. You refer to diet as being a contributor to bowel cancer. Apart from the now well known guidance, do you have any new or extra advice? Thank you for this marvellous newsletter, Barbara Stafford. Hi Barbara, Thanks for your question. A balanced diet also plays an important role in keeping a healthy weight, which after not smoking is the best way to reduce cancer risk. All of our information about diet and cancer risk can be found here: cruk. Sounds amazing, we are so lucky to have these inquisitive, knowledgeable people who will find the answers and save lives. The human body is mind blowing. Good luck to all the teams. Sounds interesting. I am based in the UK and aged I have already had primary colorectal cancer which metastasised to my ovaries and peritoneal cavity and I have had further surgery to remove these tumours. I am interested in how I could get access to the ecosystem with about 40 different bacterial species and whether this would help me longer term. Is this part of a clinical trial? Amazing work, research is a wonderful pains taking process that benefits the human race. Good luck and thank you. Fantastic news. A huge challenge but with new technology to help, it sounds very positive and is certainly on the road to eradicating certain cancers. The effect on CRC prevention can be generally attributed to several mechanisms, including suppressing inflammation [ , , ], enhancing apoptosis of early tumor cells [ , ], restoring gut barrier function and correcting microbiota composition [ ]. Two randomized-controlled trials have evaluated role of probiotics and prebiotics in CRC prevention [ , ] Table 1. Consistent with the in vitro findings, administration of selected probiotic strains and dietary fiber has shown to downregulate inflammation as evidenced by the prevention of interleukin-2 increase and reduce genotoxin exposure, which are both plausible mechanisms for CRC protection [ ]. However, despite the alteration of some CRC biomarkers and prevention of tumor atypia, results from both trials did not indicate strong evidence of CRC prevention, as ultimately the tumor occurrence rate does not differ significantly between treatment and non-treatment group [ ]. Further large-scale long-term clinical trials are needed to confirm such protective effects in clinical settings. Chemotherapy and radiotherapy are commonly employed in CRC treatment, yet their toxicities often prevent further dose escalation or lead to treatment discontinuation. Gastrointestinal mucositis is one of the most well-documented side effects, which is characterized by weight loss, diarrhea, shortening of villi, intestinal inflammation and damage to intestinal integrity [ ]. By directly altering the colonic environment, manipulating the gut microbiota is therefore hypothesized to mitigate the side effects. Various studies have shown that several probiotics strains, or their supernatant, can ameliorate chemotherapy-induced mucositis, as observed by reduced incidence of diarrhea and weight loss, primarily through suppressing inflammation [ , , ], restoring gut barrier integrity [ ] and inhibiting intrinsic apoptosis [ ]. Dietary prebiotic fiber was also found to exert beneficial effects in relieving irinotecan toxicity, accompanied by a strong correlation with increased butyrate production [ ]. Meanwhile, FMT from healthy mice to chemotherapy-treated or irradiated mice also yields promising results. By restoring gut microbiota homeostasis, FMT is shown to effectively protect mice from treatment-related gastrointestinal toxicity and improve animal survival rates [ , ]. Myelosuppression is another important dose-limiting toxicity for many chemotherapeutic agents. One study has attempted to incorporate probiotic treatment into chemotherapy and evaluate its efficacy to protect against myelosuppression in mice models. Two probiotic strains, Lactobacillus casei CRL and Lactobacillus rhamnosus CRL, are found to foster recovery of myeloid cells and neutrophils after cyclophosphamide treatment, facilitate phagocytosis in infection sites and protect mice from opportunistic infection with Candida albicans [ ]. Although the molecular mechanism of such protective effect remains unclear, this study has opened a new research direction for the clinical implications of probiotics. In view of the preclinical findings, several clinical trials have evaluated the use of probiotics in CRC patients to alleviate treatment-induced gastrointestinal side effects Table 2. These studies can be roughly classified in accordance with their clinical settings, namely during chemotherapy or radiotherapy, preoperative and postoperative management. Most of these studies have reported positive results for probiotic use in CRC management, including but not limited to reduced incidence of diarrhea [ , , , , , ] and infectious complications [ , , ], improved recovery of bowel movement [ , ], enhanced gut barrier integrity [ , ] and reduced inflammation [ ]. A study has also evaluated the use of guar gum, a potential prebiotic, in CRC patients receiving 5-FU-based chemotherapy, but such fiber does not seem to improve patient tolerability to chemotherapy [ ]. However, despite the preliminary clinical benefits demonstrated in these short-term studies, there is a lack of studies reporting the impact of probiotics on clinical outcomes, such as progression-free survival PFS and overall survival OS. Whether these clinical benefits be translated to improvement of long-term outcomes remains unknown to clinicians. In recent years, increasing interest is drawn to the potential role of gut microbiota in augmenting therapeutic efficacy of anticancer drugs. Although currently most studies are restrained to preclinical models, some promising data is reported, suggesting another possible clinical implication of gut microbiota manipulation. Modulating the gut microbiota composition is a potential strategy to improve tumor response to chemotherapeutic agents. Over a decade ago, there were some attempts of adding dietary prebiotic fiber into anticancer treatment. The study demonstrated that supplementing diet rich in inulin or oligofructose inhibits growth of transplantable tumor in mice and potentiated efficacy of 6 different cytotoxic drugs at their subtherapeutic doses. The precise mechanism was not elucidated in that study but was hypothetically mediated by the prebiotic properties of inulin and oligofructose [ ]. Meanwhile, gut microbiota depletion using antibiotics was shown to confer clinical benefits to CRC patients by overcoming chemotherapeutic resistance. The gut microbiota, specifically the intratumor bacteria, was found to induce gemcitabine resistance through enzymatic inactivation of the drug, while a gemcitabine-ciprofloxacin combination therapy abrogates resistance and potentiate treatment efficacy [ ]. Cyclophosphamide, which possesses functions of both chemotherapy as alkylating agent and immunotherapy by stimulating antitumor immune response , was shown to cause translocation of certain species of Gram-positive bacteria Lactobacillus johnsonii, Lactobacillus murinus, Enterococcus hirae into secondary lymphoid organs. Gavage treatment with Enterococcus hirae and Barnesiella intestinihominis , two proposed probiotics, has restored the drug response in antibiotic-treated mice [ ]. On the other hand, immunotherapy efficacy appears to be heavily influenced by gut microbiota composition. Oral administration of probiotics, such as Bifidobacterium species [ 92 ] and Akkermansia muciniphila [ 93 ], or FMT [ ] from treatment-responsive patients, substantially enhanced the PD1-based immunotherapy and abolished tumor outgrowth, mechanistically through the augmented dendritic cell and T cell response [ 92 ]. Although these studies are not employing CRC models, understanding how gut microbiota modulates immune response may be critical to facilitate positive therapeutic outcomes in CRC patients receiving immunotherapy, or even to overcome resistance harbored by non-responders. To our best knowledge, no clinical trials evaluating gut microbiota manipulation and treatment efficacy are published currently. A few clinical trials are initiated and now at the recruiting stage Table 3. It remains obscure whether these preclinical findings can be successfully translated to clinical application. Technological advances in taxonomic profiling have made a breakthrough in microbiome research regarding cancer pathophysiology. Accumulating preclinical evidence has suggested gut microbiota manipulation as a potential therapeutic strategy for prevention and treatment of cancer. However, before translating to bedside application, some fundamental questions are yet to be answered. At present, no quantitative definitions regarding microbial dysbiosis are available, as this concept seems to be host-specific and disease-specific [ ]. Therefore, before making a clinical decision of initiating an intervention, a clear definition and precise patient selection criteria is critical — especially when we acknowledge that those manipulating strategies do carry variable risks. The second question that ought to be answered is the prerequisite for effective intervention. Increasing studies have revealed that not all subjects respond equally to gut microbiota modulating treatment, but it highly depends on the baseline characteristics, including genetic background [ 70 ], gut barrier function [ ] and microbiome diversity [ ]. Development of personalized microbiome therapy, thus, is the key to successful clinical treatment. Lastly, data regarding human clinical trials remains sparse. Clinicians must be cautious about it and should not arbitrarily extrapolate animal data to clinical application, as cross-species translation can be potentially dangerous — the representative example will be antibiotics, which often demonstrate promising animal results but is shown to create numerous problems in clinical settings. Despite the many unknowns, we believe that gut microbiota modulation has the potential that deserves further investigation of its role in prevention and treatment of colon cancer. With continuous efforts in preclinical and clinical studies, we will be eager to see how it can be translated into clinical practice and provide additional therapeutic aids to high-risk individuals and patients. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in countries. CA Cancer J Clin. Article PubMed Google Scholar. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Parkin DM, Boyd L, Walker L. The fraction of cancer attributable to lifestyle and environmental factors in the UK in Br J Cancer. Article PubMed PubMed Central Google Scholar. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Article CAS PubMed PubMed Central Google Scholar. Kroemer G, Zitvogel L. Cancer immunotherapy in the breakthrough of the microbiota. Nat Rev Immunol. Article CAS PubMed Google Scholar. Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of microRNA Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. Article PubMed CAS Google Scholar. Chung L, Orberg ET, Geis AL, Chan JL, Fu K, DeStefano Shields CE, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther. Mackowiak PA. Recycling Metchnikoff: probiotics, the intestinal microbiome and the quest for long life. Front Public Health. Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol. Piewngam P, Zheng Y, Nguyen TH, Dickey SW, Joo HS, Villaruz AE, et al. Pathogen elimination by probiotic Bacillus via signalling interference. Kamada N, Kim YG, Sham HP, Vallance BA, Puente JL, Martens EC, et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Tuomola EM, Ouwehand AC, Salminen SJ. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol. Campana R, van Hemert S, Baffone W. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathog. Fayol-Messaoudi D, Berger CN, Coconnier-Polter MH, Lievin-Le Moal V, Servin AL. pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol. Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol. Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M. The impact of probiotics and prebiotics on the immune system. Konieczna P, Groeger D, Ziegler M, Frei R, Ferstl R, Shanahan F, et al. Bifidobacterium infantis administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, et al. Probiotic Bifidobacterium breve induces ILproducing Tr1 cells in the colon. PLoS Pathog. Ghadimi D, Helwig U, Schrezenmeir J, Heller KJ, de Vrese M. J Leukoc Biol. Chen L, Zou Y, Peng J, Lu F, Yin Y, Li F, et al. J Immunol Res. PubMed PubMed Central Google Scholar. Sichetti M, De Marco S, Pagiotti R, Traina G, Pietrella D. Anti-inflammatory effect of multistrain probiotic formulation L. rhamnosus, B. lactis, and B. Miller LE, Lehtoranta L, Lehtinen MJ. The effect of bifidobacterium animalis ssp. lactis HN on cellular immune function in healthy elderly subjects: systematic review and meta-analysis. Article PubMed Central CAS Google Scholar. Rocha-Ramirez LM, Perez-Solano RA, Castanon-Alonso SL, Moreno Guerrero SS, Ramirez Pacheco A, Garcia Garibay M, et al. Probiotic lactobacillus strains stimulate the inflammatory response and activate human macrophages. Lenoir M, Del Carmen S, Cortes-Perez NG, Lozano-Ojalvo D, Munoz-Provencio D, Chain F, et al. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol. Jacouton E, Michel ML, Torres-Maravilla E, Chain F, Langella P, Bermudez-Humaran LG. Elucidating the immune-related mechanisms by which probiotic strain lactobacillus casei BL23 displays anti-tumoral properties. Front Microbiol. Chen CC, Lin WC, Kong MS, Shi HN, Walker WA, Lin CY, et al. Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. Br J Nutr. Sanders ME, Benson A, Lebeer S, Merenstein DJ, Klaenhammer TR. Shared mechanisms among probiotic taxa: implications for general probiotic claims. Curr Opin Biotechnol. Mohamadzadeh M, Pfeiler EA, Brown JB, Zadeh M, Gramarossa M, Managlia E, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA. Khazaie K, Zadeh M, Khan MW, Bere P, Gounari F, Dennis K, et al. Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM. Increased tight junctional permeability is associated with the development of colon cancer. Puppa MJ, White JP, Sato S, Cairns M, Baynes JW, Carson JA. Biochim Biophys Acta. Ahmad R, Kumar B, Chen Z, Chen X, Muller D, Lele SM, et al. Alvarez CS, Badia J, Bosch M, Gimenez R, Baldoma L. Outer membrane vesicles and soluble factors released by probiotic escherichia coli nissle and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. Wang L, Cao H, Liu L, Wang B, Walker WA, Acra SA, et al. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein. J Biol Chem. Martin R, Chamignon C, Mhedbi-Hajri N, Chain F, Derrien M, Escribano-Vazquez U, et al. The potential probiotic Lactobacillus rhamnosus CNCM I strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. Sci Rep. Article PubMed PubMed Central CAS Google Scholar. Kumar M, Kissoon-Singh V, Coria AL, Moreau F, Chadee K. Probiotic mixture VSL 3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. Am J Physiol Gastrointest Liver Physiol. Cannon J, Lee T, Bolanos J, Danziger L. Pathogenic relevance of Lactobacillus: a retrospective review of over cases. Eur J Clin Microbiol Infect Dis. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. Hassan H, Rompola M, Glaser A, Kinsey SE, Phillips R. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer. Sitaraman R. Prokaryotic horizontal gene transfer within the human holobiont: ecological-evolutionary inferences, implications and possibilities. Article Google Scholar. Hu Y, Yang X, Qin J, Lu N, Cheng G, Wu N, et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach JT, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes. Chang L, Zhang Z-Y, Ke D, Jian-Ping Y, Xiao-Kui G. Antibiotic resistance of probiotic strains of lactic acid bacteria isolated from marketed foods and drugs. Biomed Environ Sci. Gueimonde M, Sánchez B, de los Reyes-Gavilán CG, Margolles A. Antibiotic resistance in probiotic bacteria. Jacobsen L, Wilcks A, Hammer K, Huys G, Gevers D, Andersen SR. Horizontal transfer of tet M and erm B resistance plasmids from food strains of Lactobacillus plantarum to Enterococcus faecalis JH in the gastrointestinal tract of gnotobiotic rats. FEMS Microbiol Ecol. Toomey N, Monaghan A, Fanning S, Bolton DJ. Assessment of antimicrobial resistance transfer between lactic acid bacteria and potential foodborne pathogens using in vitro methods and mating in a food matrix. Foodborne Pathog Dis. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics ISAPP consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. Gibson GR, Fuller R. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Azcarate-Peril MA, Ritter AJ, Savaiano D, Monteagudo-Mera A, Anderson C, Magness ST, et al. Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals. Maier TV, Lucio M, Lee LH, VerBerkmoes NC, Brislawn CJ, Bernhardt J, et al. Impact of dietary resistant starch on the human gut microbiome, metaproteome, and metabolome. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, et al. Wong JM, De Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. Canani RB, Di Costanzo M, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. Tong L-c WangY, Wang Z-b LiuW-y, Sun S, Li L, et al. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress. Front Pharm. Google Scholar. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Forchielli ML, Walker WA. The role of gut-associated lymphoid tissues and mucosal defence. Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun. Monteagudo-Mera A, Rastall RA, Gibson GR, Charalampopoulos D, Chatzifragkou A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Ito H, Takemura N, Sonoyama K, Kawagishi H, Topping DL, Conlon MA, et al. Degree of polymerization of inulin-type fructans differentially affects number of lactic acid bacteria, intestinal immune functions, and immunoglobulin A secretion in the rat cecum. J Agric Food Chem. Belcheva A, Irrazabal T, Robertson SJ, Streutker C, Maughan H, Rubino S, et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Bultman SJ, Jobin C. Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite? Singh V, San Yeoh B, Chassaing B, Xiao X, Saha P, Olvera RA, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Konstantinov SR, Kuipers EJ, Peppelenbosch MP. Functional genomic analyses of the gut microbiota for CRC screening. Yan F, Polk DB. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Wang Y, Liu L, Moore DJ, Shen X, Peek R, Acra SA, et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol. De Marco S, Sichetti M, Muradyan D, Piccioni M, Traina G, Pagiotti R, et al. Probiotic cell-free supernatants exhibited anti-inflammatory and antioxidant activity on human gut epithelial cells and macrophages stimulated with LPS. Evid Based Complement Altern Med. Bermudez-Brito M, Muñoz-Quezada S, Gomez-Llorente C, Matencio E, Bernal MJ, Romero F, et al. Cell-free culture supernatant of Bifidobacterium breve CNCM I decreases pro-inflammatory cytokines in human dendritic cells challenged with Salmonella typhi through TLR activation. PLoS ONE. Gao J, Li Y, Wan Y, Hu T, Liu L, Yang S, et al. A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function. Chen Z-Y, Hsieh Y-M, Huang C-C, Tsai C-C. Inhibitory effects of probiotic Lactobacillus on the growth of human colonic carcinoma cell line HT Escamilla J, Lane MA, Maitin V. Cell-free supernatants from probiotic Lactobacillus casei and Lactobacillus rhamnosus GG decrease colon cancer cell invasion in vitro. Nutr Cancer. Konishi H, Fujiya M, Tanaka H, Ueno N, Moriichi K, Sasajima J, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, et al. The gut microbiome modulates colon tumorigenesis. Cao H, Xu M, Dong W, Deng B, Wang S, Zhang Y, et al. Int J Cancer. Zackular JP, Baxter NT, Chen GY, Schloss PD. Manipulation of the gut microbiota reveals role in colon tumorigenesis. |
Ich denke, dass Sie nicht recht sind. Ich kann die Position verteidigen. Schreiben Sie mir in PM, wir werden reden.